| HeFH only, 25 patients | CVD only, 25 patients | HeFH & CVD, 19 patients | Total cohort, 69 patients |
---|---|---|---|---|
Entry LDLC 25th, 50th, 75th percentile [141, 156, 181Â mg/dl] | Entry LDLC 25th, 50th, 75th percentile [90, 110, 149Â mg/dl] | Entry LDLC 25th, 50th, 75th percentile [106, 156, 204Â mg/dl] | Entry LDLC 25th, 50th, 75th percentile [110, 143, 172Â mg/dl] | |
 | number (%) of patients had LDLC < 70 mg/dl at least once during follow up, number (%) of measures with LDLC <70 mg/dl during follow up | |||
ALI 75Â mg/2Â weeks Total 29 patients 65 LDLC measurements | 2/6 (33%) patients 8/17 (47%) LDLC measurements | 11/17 (65%) patients 22/35 (63%) LDLC measurements | 2/6 (33%) patients 8/13 (62%) LDLC measurements | 15/29 (52%) patients 38/65 (58%) LDLC measurements |
ALI-EVO Total 40 patients 59 LDLC measurements | 9/19 (47%) patients 12/27 (44%) LDLC measurements | 6/8 (75%) patients 9/12 (75%) LDLC measurements | 5/13 (38%) patients 7/20 (35%) LDLC measurements | 20/40 (50%) patients 28/59 (47%) LDLC measurements |
All treatment groups Total 69 patients 124 LDLC measurements | 11/25 (44%) patients 20/44 (45%) LDLC measurements | 17/25 (68%) patients 31/47 (66%) LDLC measurements | 7/19 (37%) patients 15/33 (45%) LDLC measurements | 35/69 (51%) patients 66/124 (53%) LDLC measurements |